Moving rare disease innovationfrom scientific promiseto real-world access.
Pharma²⁸ builds the clinical, regulatory and data infrastructure that connects rare and ultra-rare disease therapies to the patients who need them — across Brazil and the international biotech ecosystem.
A biotech and health technology company for rare and ultra-rare disease.
We operate at the intersection of therapeutic innovation, clinical infrastructure and data intelligence.
We partner with biotech developers, hospitals, investigators, academic institutions and patient communities to shorten the distance between a promising molecule and a treated patient.
Rare disease pathways are fragmented — by geography, by data, by design.
Therapies exist but never reach the patients they were built for. Diagnostic journeys stretch across years. Clinical infrastructure is inconsistent. Regulatory pathways vary. Data lives in silos.
The gap is not scientific. It is structural.
A proprietary intelligence layer for rare disease.
We are building a data infrastructure that structures clinical signals, phenotypic patterns and real-world evidence into decision-useful intelligence for developers, investigators and access teams.
The platform supports — never replaces — clinical judgment.
Six coordinated capabilities. One pathway.
Regulatory & Market Entry
Navigate ANVISA, CONITEC and access frameworks with disease-specific rigor.
Clinical & Institutional Partnerships
Activate hospitals, investigators and academic centers across Brazil.
Patient Identification & Diagnostic Support
Shorten the diagnostic journey with structured signals and coordination.
Data & Bioinformatics Intelligence
Turn phenotypes, cohorts and real-world data into actionable evidence.
Access & Distribution Coordination
Design continuity of care through the last mile of delivery.
Boston Biotech Business Development
Bridge Kendall Square to Brazilian clinical infrastructure.
One coordinated pathway, not a chain of vendors.
- 01Assess
Disease, molecule, evidence base, regulatory context and cohort geography.
- 02Design
A tailored clinical, regulatory and data plan grounded in Brazilian realities.
- 03Activate
Sites, investigators, institutional agreements, ethics submissions.
- 04Execute
Clinical operations, real-world evidence, patient identification.
- 05Sustain
Access, distribution, longitudinal data, cohort continuity.
A continental-scale clinical environment with unique cohort diversity.
Brazil offers phenotypic richness, tertiary medical centers of international caliber, and public and private health systems that — when navigated with discipline — accelerate real-world evidence generation.
Embedded where global biotech is built.
We operate inside the Boston–Kendall Square ecosystem and translate its cadence into Brazilian execution — a corridor of scientific fluency and clinical depth.
Aligned with the people who move rare disease forward.
Biotech developers
Programs advancing therapies for rare and ultra-rare conditions.
Investors & strategic partners
Capital and platforms building the next decade of rare disease infrastructure.
Hospitals & investigators
Institutions ready to host rigorous clinical programs.
Patient organizations
Communities carrying the lived experience of rare disease.
Bringing Small Molecules to Life
A strategic brief on translating rare disease innovation across the Boston–Brazil corridor.
Building rare disease infrastructure, together.
If you are advancing a therapy, investing in the space, running a clinical program or coordinating patient identification — start a conversation with us.